Clinically, side effects of SGLT2 inhibitors, such as polyuria and polydipsia, have been reported during the early stages of treatment1, 2, which leads to the restriction of use of an SGLT2 inhibitor, particularly in patients with chronic kidney disease (CKD). This evidence concerns the gene SLC5A2 and chronic kidney disease.